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Summary
 
Previous studies have demonstrated that T cell–reactive antibodies in HIV-1 infection contrib-
ute to lymphocyte depletion by cytotoxicity that involves differential membrane targets, such
as the 43.5-kD receptor on CEM cells. Here, we show that these antibodies bind Fas as result
of a molecular mimicry of the gp120. Both flow cytometry and immunoblotting using the hu-
man Fas-transfected mouse WC8 lymphoma revealed positive binding of immunoglobulin G
from several patients to a 43.8-kD membrane receptor that also reacts with the CH11 anti-Fas
monoclonal antibody. Specificity to Fas was further confirmed to chimeric recombinant hu-
man Fas-Fc by ELISA, whereas overlapping peptide mapping of a Fas domain (VEINCTR–N)
shared by gp120 V3 loop demonstrated a predominant affinity to the full-length 10-mer pep-
tide. Four anti-Fas affinity preparations greatly increased the subdiploid DNA peak of CEM
cells similar to agonist ligands of Fas. In addition, anti-Fas immunoglobulin G strongly inhib-
 
ited the [
 
3
 
H]thymidine uptake of CEM cells in proliferative assays, inducing a suppression as
high as provoked by both CH11 mAb and recombinant human Fas ligand. Since anti-Fas were
reactive to gp120, it is conceivable that antibodies binding that domain within the V3 region
are effective cross-linkers of Fas and increase apoptosis in peripheral T cells. These results sug-
gest that autologous stimulation of the Fas pathway, rather than of lymphocytotoxic antibodies,
 
may aggravate lymphopenia in a number of HIV-1
 
1
 
 subjects.
 
A
 
ctivation-induced apoptosis of antigen-primed CD4
 
1
 
and CD8
 
1
 
 T lymphocytes has been well documented
in peripheral cell cultures from HIV-1
 
1
 
 patients, and has
been postulated as a mechanism that is primarily involved
in the immunopathogenesis of AIDS (1–4). Chronic im-
mune activation of those cells is indeed thought to signifi-
cantly enhance their susceptibility to apoptosis (5–7), whereas
the subsequent antigenic stimuli may drive the death pro-
gram to completion (8, 9).
Apoptosis is a signal-dependent suicidal process that is
regulated in part by Fas or Apo1/CD95 (10–13), namely a
45-kD membrane receptor that transduces the death signal
to its intracellular pathway after ligation with a natural
ligand (Fas-L)
 
1
 
 active in trimeric form (14). Fas-mediated
apoptosis makes a physiological contribution within the
immune system in suppression of autoreactive T cell clones
in the thymus (15), as well as in the regulation of its normal
response (16) and cytotoxicity (17). Moreover, the mutated
expression of genes encoding either Fas or Fas-L may af-
ford resistance to apoptosis in mature T cells from 
 
lpr
 
 (18)
or 
 
gld
 
 (19) mice, respectively. Both phenotype strains suffer
from a lymphoproliferative disorder that leads to autoim-
mune syndromes (20) that are highly similar to SLE. In this
disorder, the abnormal expression of soluble Fas (21) is as-
sociated with an increased rate of apoptosis in peripheral
lymphocytes (22), suggesting the involvement of Fas dereg-
ulation in driving the SLE autoreactivity. Further evidence
of the role of apoptosis in human autoimmunity has been
provided by the demonstration that synovial cells from pa-
tients with rheumatoid arthritis are highly subject to death
by Fas overexpression (23).
Autoimmunity (24–26) and Fas overexpression (27, 28)
have also been described during the HIV-1 infection, even
though no linkage between these conditions has been doc-
umented so far. We have recently reported that the abnormal
overexpression of Fas by T cells in advanced HIV-1 infec-
tion correlates with the high responsiveness of the receptor
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid; CDC, Center for Disease
Control and Prevention; PI, propidium iodide; RF, rheumatoid factor;
rFas-L, recombinant human Fas ligand.
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to its extracellular binding, even when using a monomeric
ligand, as provided by mouse IgG1 mAb from the UB-2
clone (29). This finding emphasizes the hypothesis that Fas
is somehow involved in the increased in vitro apoptosis of
peripheral cells from HIV-1–infected individuals, and that
the Fas pathway may play a pathogenic role by aggravating
the T cell lymphopenia that is related to the progression of
their disease. Aggravation has also been associated to au-
toimmune phenomena (30–32), and we have illustrated the
lymphopenic effect of T cell–reactive autoantibodies in a
considerable number of patients, since their serum levels
apparently parallel the progression of CD4
 
1
 
 lymphocyte
decline (33, 34). As a result of their ability to react with a
43.5-kD marker located on CD4
 
1
 
 clonotypic lymphoblasts
of the CEM line, these molecules were found to be power-
ful inducers of cytolysis in complement-mediated cytotox-
icity, when either peripheral T lymphocytes or CEM were
used as the cell target (35).
In the present study, we provide evidence that in most
patients with variable serum titers of T cell binding anti-
bodies, the molecular target of these reactivities may in-
clude Fas. Therefore, activation of the Fas pathway by au-
toantibodies is at least partly responsible for the increased
apoptosis that contributes to T cell depletion because of the
receptor’s high sensitivity. Since antibodies to Fas are also
reactive to a specific epitope shared by the gp120 V3 loop
of HIV-1, however, it is conceivable that antibodies prima-
rily elicited to neutralize the virus may cross-react with Fas
and activate its function through molecular mimicry. The
increment of apoptosis by autologous Fas stimulation rather
than lymphocytotoxic antibodies may therefore account for
the aggravation of lymphopenia in patients whose HIV-
1–neutralizing IgG may include specificity to the viral do-
main shared by Fas.
 
Materials and Methods
 
Study Subjects.
 
Peripheral blood samples were obtained from
74 HIV-1
 
1
 
 individuals at different Center for Disease Control
and Prevention (CDC) stages (36) who were hospitalized at the
Department of Internal Medicine and Oncology of the Univer-
sity of Bari. The study group included 55 former intravenous
drug users, 10 homosexual men who admitted to occasional in-
travenous drug use, 7 heterosexual women with no history of in-
travenous drug use, and 2 hemophiliac men. 67 uninfected do-
nors provided control blood samples. All subjects gave their
informed consent, and the study was approved by the ethical
committee of the University of Bari. In most instances, sera were
aliquoted and stored at 
 
2
 
80
 
8
 
C until use.
 
Detection of T cell–reactive Antibodies.
 
Sera were screened for
the presence of antibodies to T cell membrane by an optimized
ELISA, using the CEM plasma membrane extract as antigen (34).
Briefly, the 96 flat-well microtiter plates were coated overnight
with 10 
 
m
 
g/ml of lysed membrane and were further incubated for
3 h with sera diluted 1/200. The plates were then supplemented
with a goat peroxidase–conjugated anti–human IgG and in paral-
lel with anti-IgM antiserum, and were subsequently read in a mi-
cro-ELISA reader (Titertek; Flow Laboratories, Irvine, Scotland)
after their OPD (
 
O
 
-phenylenediamine) color development. Each
sample was tested in triplicate, and each test included the control
group. Patients’ sera with absorbance higher than the mean 
 
1
 
 3
SD of control values in each isotype test were considered positive
for antibody detection.
 
Anti-Fas Specificity of T Cell–reactive Antibodies.
 
A number of
different approaches were adopted to investigate the affinity of
CEM-reactive IgG and IgM to Fas. First, we used indirect immu-
nofluorescence analysis with the murine WC8 lymphoma cell
line transfected with human Fas as substrate, and its Fas-negative
mutant WR19L as a control (37). Preliminary experiments in-
cluded the preparation of cytocentrifuged cell suspensions from
both cell lines, followed by incubation with sera and subsequent
treatment with the FITC-conjugated rabbit anti–human IgG and
IgM. The slides were then evaluated under a UV microscope.
Furthermore, the sera were tested in a flow cytometry assay, using
a FACScan
 
Ò
 
 (Becton Dickinson & Co., Mountain View, CA). 3 
 
3
 
10
 
5
 
 cells from each line were separately incubated with 50 
 
m
 
l of
serum diluted 1/80, and then washed and further treated with the
FITC-conjugated antiserum to each class of antibody. Control
cell preparations were incubated with anti-T negative sera de-
rived from both patients and controls, whereas an additional
check included the treatment of cell suspensions with polyspecific
human IgG from commercial preparations, as well as the incuba-
tion of cell preparations with only the labeled antisera.
The second approach included immunoblotting analysis, using
the membrane lysate from both WC8 and WR19L cell lines as a
substrate. Purified plasma membrane extract was obtained by
nonionic detergent lysis followed by sequential centrifugations at
400 and 100,000
 
g
 
 for clearance of nuclei, as well as the removal
of the cytoskeletal component and insolubilized membrane, re-
spectively. The membranes were then run in PAGE and further
electroblotted to nitrocellulose. Strips cut from the nitrocellulose
sheet were incubated with serum samples diluted 1/50, and were
then washed and treated with alkaline phosphatase–labeled anti-
sera to IgG and IgM until the nitro blue tetrazolium chromogenic
staining completed the test. The molecular weights of the bands
detected by the enzyme-labeled antiserum were evaluated by a
standard migration curve obtained in each test by rainbow-col-
ored markers (Amersham International, Bucks, UK).
An evaluation was also made of the specificity detected in both
flow cytometry and immunoblotting by an additional ELISA, us-
ing the recombinant human Fas (rFas) as antigen. This substrate is
a chimeric protein product, since it is conjugated to the Fc por-
tion of human IgG to optimize the biological stability (12). The
ELISA was then installed by coating the plates with 10 
 
m
 
g/ml of
antigen and subsequent incubation of sera diluted 1/100 for 5 h.
Equivalent concentrations of mouse mAb anti–human 
 
k
 
 and 
 
l
 
light chains (Immunotech, Marseille, France) were added to the
wells, and the test was completed using a goat peroxidase–conju-
gated anti–mouse IgG. Parallel control ELISA plates coated with
Fc fragment alone were prepared with the same mAbs and labeled
antiserum to calculate the basic reactivity to Fc potentially present
in anti-rFas specificities. The anti-Fc ELISA, including the mea-
surement of IgM rheumatoid factor (RF) levels, was performed
concurrently to the anti-rFas assay, whose values were referred to
as the relative anti-Fc reactivities. Four RF-positive sera from
HIV-1–uninfected patients were also tested as controls.
 
Evaluation of Specificity to Sequential Peptides of Fas.
 
Sera with pos-
itive anti-rFas–reactivity values were also investigated to define
their molecular specificity to peculiar epitopes of the Fas mole-
cule by peptides produced by an automated synthesizer (Bio-
chrom Biolynx 4170; LKB, Sweden) by Fmoc chemistry, accord-
ing to the manufacturer’s protocols. Thus, we installed a new 
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ELISA using as substrate 10-mer overlapping peptides resembling
the linear sequence of Fas between 90 and 117 amino acid (aa)
positions. Conformity of peptide binding to plates was assessed by
parallel tests using KLH as a carrier protein (38) with respect to
uncoupled peptides. Since all 10-mer peptides appeared to bind
the ELISA solid phase equally efficiently as in their glutaralde-
hyde–KLH-coupled form, the plates were coated with uncoupled
antigen to prevent any cross-reactivity with KLH (39). Peptides
included the 8-aa stretch (VEINCTR–N; position: 99–108 of
Fas) structurally shared by the third N-glycosylation site of the
gp120 V3 loop (40). This sequence is invariably expressed by the
HIV-1
 
iiib
 
 strain during both primary infection and advanced dis-
ease (41), whereas a single substitution of Glu (E) by Gln (Q) oc-
curs within the domain in the V3 loop from other virus sub-
groups, including HIV-1
 
mn
 
 and HIV-1
 
rf
 
 (42). Therefore, we
used the 17 overlapping peptides of VEINCTR–N to test its pro-
gressive aa antigenicity, whereas the VEINCTRPNN (IIIB strain)
and VQINCTRPNY (MN strain) single peptides were also coated
in parallel plates. This control was addressed to evaluate a poten-
tial prevalence in specific HIV-1 strain infection. After incuba-
tion, the plates were supplemented with sera, and the assay was
completed as a standard ELISA.
 
Isolation of Anti-Fas Antibodies.
 
Sequential affinity chromatog-
raphy was used to purify antibodies to Fas from sera 3, 41, 54, and
59, which displayed the highest reactivity to the antigen in the
previous ELISAs. Purified anti-Fas preparations were obtained by
recycling absorption of 7–12 ml of serum on Sepharose 4B col-
umns coupled with the WC8 membrane lysate. The absorbed
material was then eluted by glycine-HCl acidic buffer (pH 2.8)
and promptly adjusted to neutrality by the addition of Tris base
(pH 8.3). Next, the eluates were repeatedly passed through
WR19L lysate affinity columns to absorb possible unrelated spec-
ificities on the Fas-negative parental cell line. In two instances
(sera 54 and 59), we optimized these purification experiments by
absorption on VEINCTR-coupled Sepharose columns. The pro-
tein content of eluted fractions was assessed by SDS-PAGE,
whereas aliquots of these affinity-isolated anti-Fas antibodies were
dialyzed against PBS and sterilized by filtration for functional
studies. In addition, their ability to bind to HIV-1 glycoproteins
was also tested by a commercial immunoblotting kit (HIV Blot
2.2; Diagnostic Biotechnology Ltd., Singapore). IgG from HIV-1
 
1
 
sera unreactive to Fas (Nos. 9 and 34 from group B) were puri-
fied by DEAE- cellulose filtration to provide adequate controls to
anti-Fas specificities from group A patients.
 
Functional Tests of Anti-Fas Antibodies.
 
The ability of purified
anti-Fas antibodies to induce apoptosis in vitro was investigated
by using both CEM cells and peripheral T lymphocytes as the tar-
get in separate tests. To this purpose, 5 
 
3
 
 10
 
5
 
 CEM or T cells,
purified by double-gradient centrifugation from patients 3, 41,
and 54, were incubated for 20 h in the presence of 10 ng/ml IL-2
in 24-well plates coated with variable concentrations (0.1–10 
 
m
 
g/ml)
of anti-Fas molecules (16). The cells were then washed and
stained by the propidium iodide (PI) method to measure the ex-
tent of subdiploid DNA content as a degree of apoptosis (43).
[
 
3
 
H]thymidine uptake was also measured to determine the inhibi-
tion of cell proliferation after anti-Fas incubation (29). The nega-
tive controls in both experiments were IgG from anti-CEM neg-
ative patients (Nos. 9 and 34), while the positive control included
incubation of parallel cell preparations, with the CH11 mAb and
the rFas-L at amounts similar to those adopted for anti-Fas anti-
bodies. Control experiments investigated the possible inhibition
of anti-Fas antibodies by the VEINCTR peptide and the rgp120
(Intracel, London, UK). To this purpose, anti-Fas molecules were
separately preincubated with variable amounts (up to 7.5 
 
m
 
g/ml
of VEINCTR and 1 
 
m
 
g/ml of rgp120) for 3 h and then used in
functional tests.
 
Statistical Analysis.
 
Sera with ELISA OD values higher than
mean
 
1
 
3 SD of controls were considered positive. The distribu-
tion of subdiploid DNA content in peripheral T cells from pa-
tients showing ELISA positivities was also sought by the Wil-
coxon test as a nonparametric method. In several instances,
Student’s 
 
t
 
 test was also used to compare means from different
samples within groups.
 
Results
 
T Cell–reactive Antibodies in HIV-1
 
1
 
 Patients.
 
Fig. 1 shows
the distribution of both IgG and IgM reactivities to the
CEM plasma membrane. In line with our previous obser-
vations (34), we found that the majority of isolated specificities
were of the IgG isotype. This pattern was predominant in
seven patients, whereas four showed elevations of IgM
only. In addition, a subgroup of five patients was positive
for both IgG and IgM, though the OD values of IgG reac-
Figure 1. Distribution of serum IgG and IgM reactivities by ELISA to
CEM cell membrane in 74 HIV-1–infected individuals at different CDC
stages. Positive antibody titers were observed in 16 patients divided into
groups A, B, and C in relation to serological elevations of IgG, IgM, or
both. Numbers refer to both HIV-11 patients and two normal donors
(ND) showing weak yet definite IgM elevations to the membrane. The
reactivities of the remaining 58 HIV-11 sera are included in the shaded
area whose positivity limits are the mean 1 3 SD of OD values obtained
from 67 uninfected controls. SD of single samples are related to outlayer
values. 
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tivity were constantly higher within each serum. Therefore,
we arbitrarily placed these patients in groups A, B, and C,
depending on their serum positivities of IgG, IgM, or both.
Two control subjects also displayed a moderate, though
definite IgM positivity.
 
CEM Membrane–reactive Antibodies and Specificity to Fas.
 
Preliminary experiments addressed the question whether
the T cell–reactive antibodies detected by ELISA were able
to bind Fas. Sera from the A, B, and C groups were first in-
vestigated by both immunofluorescence and immunoblot-
ting analyses, using the human Fas-transfected WC8 lympho-
blasts as the substrate. Results were related to the anti-CEM
ELISA, and are expressed in Table 1 along with relative
values of peripheral counts of T cells and their subdiploid
DNA extent. As shown, although small numbers of com-
parable patients were available, serum positivities to T cell
membranes were in apparent concordance using differential
methods, whereas the distribution of the subdiploid DNA
extent of group A was apparently different (
 
P
 
 
 
,
 
0.05) from
that of group B. By contrast, CD4
 
1
 
 T cell lymphopenia
was always related to the clinical stage, though the lowest
values were noted in selected instances from groups A and C.
Representative patterns of positive immunofluorescence
tests are illustrated in Fig. 2, where the upper section of A
shows the fluorescence obtained by incubating serum 41
with WC8 and further treatment with FITC–anti–human
IgG. This pattern was not evident when the same serum
was incubated with the Fas-negative parental cell line
WR19L (lower section), suggesting a relative specificity of
IgG to the transfected antigen. A similar profile of positiv-
ity was also observed in the other sera from group A and,
to a variable extent, in sera from group C. Conversely, sera
from group B constantly showed a pattern of weak fluores-
cence in tests using FITC–anti-IgM as the related antise-
rum (data not shown). Similar evidence of feeble reactivity
to WC8 was also detected in IgM from the two controls
(ND-11 and ND-28) with positive binding to CEM in
ELISA.
Cytofluorimetric analysis for anti-Fas is presented in Fig.
2 
 
B
 
, which shows a differential pattern of reactivity within
the sera tested. While no binding to WR19L was observed
in all instances, a variable reactivity to WC8 was recorded
in relation to the isotype tested. IgG in sera from groups A
and C were highly reactive to the Fas
 
1
 
 cell line, albeit in
the presence of slight variations of fluorescence intensity
(even more than one decade of dynamic range than
WR19L) within different samples. By contrast, IgM in sera
from groups B and C uniformly showed a weak to unde-
Figure 2. (A) Indirect immunofluorescence assay using as substrate the human Fas transfected mouse WC8 lymphoma (top) and its Fas-negative mutant
WR19L (bottom). Representative fluorescence pattern from patient 41, whose serum IgG were reactive to the WC8 membrane with no evidence of spec-
ificity to Fas-negative cells. (B) Flow cytometry analysis of Fas reactivity of T cell–reactive IgG and IgM detected by ELISA in HIV-1–infected individu-
als. Positive binding of IgG to the antigen occurred in virtually all patients included in groups A and C, showing high fluorescence intensity to WC8 cell,
as compared to its Fas-negative parental line (WR19L). By contrast, the reactivity of IgM to WC8 was almost undetectable, since the fluorescence inten-
sity was less than one decade of dynamic range of the Fas-negative control. (C) Cytofluorimetric control tests of patients unreactive to CEM membrane
and normal donors (ND). Representative patterns from both groups consistently showed lack of IgG and IgM reactivity to the human Fas–transfected cell
line (WC8). Pt., patient. 
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tectable affinity to the WC8 membrane, since in most in-
stances, their extent of fluorescence intensity was similar to
WR19L cells. This difference supported the contention
that IgG rather than IgM are highly reactive molecules to
Fas. Control patterns from a number of CEM-unreactive
patients and uninfected donors are shown in Fig. 2 
 
C.
 
 No
evidence of positive binding to WC8 cells was demon-
strated in both IgG and IgM from these control subjects, al-
though in selected instances, such as in normal donor 28,
the low fluorescence of IgM to the Fas
 
1
 
 membrane paral-
leled the moderate ELISA elevation.
Anti-Fas specificities were also determined by immuno-
blotting, using both WC8- and WR19L-purified mem-
branes as substrates (Fig. 3). Once again, sera from groups
A and C were reactive to a few low molecular weight
bands on both lysates (upper section). IgG in most sera,
however, showed a variable reactivity to a defined band
that was evident only on the WC8 plasma membrane. The
target antigen was apparently related to Fas, since it was re-
 
active to the commercial mAb from clone CH11 and ex-
hibited a similar molecular mass (
 
z
 
43.8 kD) in our assay.
Although more specific than immunofluorescence, how-
ever, the binding to blotted Fas by IgG from group C pa-
tients was of variable intensity, in contrast with the unde-
tectable IgM reactivity (data not shown). The lower section
of Fig. 3 shows the immunoblotting pattern of CEM-unre-
active patients and healthy controls. These experiments
confirmed the absence of definite specificities to Fas in sera
from both control groups.
Binding to Fas was further investigated with an opti-
mized ELISA, using the rFas-Fc as antigen. The amplitude
of reactivity to Fas compared with the concurrent activity
to Fc is shown in Fig. 4. A broad variation in the ability to
bind the antigen was observed. High OD values were de-
tected in group A, particularly in patients 3, 41, and 54,
suggesting a remarkable correlation with the anti-CEM
ELISA, whereas the total activity to rFas-Fc was apparently
modest in group B and still substantial in group C. How-
 
Table 1.
 
Clinical and Immunity Parameters of 16 HIV-1
 
1
 
 Patients
 
Sera
CDC
Stage
Peripheral
lymphocytes CD4
 
1
 
CD8
 
1
 
Peripheral T cells
with subdiploid
DNA (percentage
of PI staining)
Anti-Fas IgG
Anti-Fas
IgM
FC
 
*
 
WB
 
‡
 
FC WB
 
cells/
 
m
 
l cells/
 
m
 
l cells/
 
m
 
l
 
Patients
Group A: No.  3 IV 690 122 467 43.5
 
11 2 2
 
12 III 809 212 494 39.6
 
11 2 2
 
21 II 1,390 381 724 32.5
 
11 6 2
 
39 IV 1,018 172 715 40.8
 
11 2 2
 
41 IVC 595 47 380 46.5
 
11 6 2
 
54 IV 270 8 165 38.0
 
11 2 2
 
63 III 780 190 515 40.8
 
11 2 2
 
Group B: No.  9 IV 872 73 487 31.5
 
22 6 2
 
34 II 2,907 705 1,708 21.9
 
22 6 2
 
61 IV 965 153 565 27.5
 
22 2 2
 
78 III 706 224 503 33.0
 
62 2 2
 
Group C: No. 19 III 954 288 527 37.5
 
11 6 2
 
28 IV 550 107 308 41.5
 
12 2 2
 
43 III 1,615 317 980 29.5
 
12 6 2
 
59 IVC 675 28 426 43.2 11 6 2
81 III 1,136 209 690 40.5 16 2 2
Uninfected controls
ND-11 — 2,790 1,786 792 9.7 22 6 2
ND-28 — 4,170 2,045 1,215 11.2 22 2 2
Clinical and immunity parameters included the amplitude of the apoptotic T cell population, as measured by the content of subdiploid DNA. The
peripheral lymphocytes from the 16 HIV-11 patients showed serological reactivities to CEM membrane antigens and to human Fas–transfected
mouse WC8 lymphoma cells. Data from two uninfected controls were presented in relation to their positivity detected in ELISA to CEM mem-
brane.
*FC, flow cytometry. The positivity was related to a fluorescence intensity higher than one decade of dynamic range of the relative control.
‡WB, western blot. Positivity detection of a Fas-related band indicated as 1.2293 Silvestris et al.
ever, specificity to rFas was predominant in most sera from
group A when compared to the single reactivities to Fc.
Both total and IgM specificities to Fc were considerably
expressed in sera from group C, suggesting that, in contrast
with the potential involvement of RFs in increasing posi-
tivities to the T cell membrane, a clear-cut specificity to Fas
was definitely present. Conversely, 39 patients unreactive
to the CEM membrane showed no similar elevations of
anti-Fas specificities in their sera, whereas, as expected,
control RF-positive sera were highly reactive to Fc both in
its natural and chimeric forms. In addition, the uninfected
controls were constantly unreactive to the antigen (data not
shown).
Anti-Fas IgG Show Predominant Reactivity to VEINCTR–N
Domain. The next set of experiments investigated whether
anti-Fas IgG in sera from groups A and C were reactive to
the aa 99–108 stretch of Fas, which is also shared by the V3
loop of gp120. To this purpose, the ELISA was prepared
with overlapping peptides of this domain and those resembling
the V3-related homology sequence from both HIV-1iiib
and HIV-1mn as the antigen. The results obtained with the
most reactive sera (Nos. 3, 41, and 54) showed signifi-
cant binding starting with peptide 96GLEVEINCTR105 (Fig.
5 A) and stable until 100EINCTRTQNT109, supporting the
evidence that the shared stretch alone could constitute the
reactive epitope. Interestingly, construction of the peptide
with N (Asn) in aa position 108 induced a small but definite
increment of reactivity in IgG from serum 54. This was con-
sistent with a potential contribution of Asn to a conforma-
tional rather than a linear domain reacting with those anti-
bodies. Moderate and low IgM reactivities (OD ,0.31) to
the full-length peptide were observed in two sera from
group B (Nos. 34 and 78), whereas parallel ELISA tests
searching for potential specificities to the peptide in sera
from patients who were unreactive to CEM membrane and
from uninfected donors revealed a prevalent lack of reac-
tivity in both control groups (data not shown).
Fig. 5 B illustrates the pattern of IgG reactivities for the
peptides that resemble the homology sequence. Predomi-
nant binding to VEINCTRPNN (V3iiib) was observed in
most sera from both groups. The difference between reac-
tivities to VEINCTRPNN(iiib) and VQINCTRPNY(mn)
was evident in several sera (Nos. 3, 21, and 41), whereas
the similar values for both peptides by IgG of serum 54 fur-
ther supported the view that the presence of Asn, rather
than the substitution of Glu by Gln, is essential in influenc-
ing the antigenicity of both epitopes. As expected, IgG
from the controls constantly showed low values of reactivi-
ties to both peptides.
Affinity-isolated Anti-Fas Preparations. Serum samples from
patients 3, 41, 54, and 59 containing anti-Fas were passed
through Sepharose 4B columns coupled with WC8 mem-
brane lysate and were further cleared of nonspecific anti-
bodies by absorption on WR19L affinity columns. Fig. 6
shows the protein analysis of relative eluates detected by
SDS-PAGE, using b-mercaptoethanol as the reducing agent.
A prevalent IgG content was demonstrable in all samples
absorbed on the lysates, even in the presence of traces of
IgM, particularly in sera 41 and 59. Similarly, eluates from
VEINCTR columns included IgG, although at lower con-
centrations than in other eluted fractions.
Anti-Fas IgG Are Inducers of Apoptosis in Vitro. The ability
of purified anti-Fas preparations to induce cell death was
investigated in vitro by different methods, including the
measurement of both subdiploid DNA content and prolif-
erative rate inhibition of target cells after their incubation
with those antibodies. To this end, we used both CEM
cells as a clonotypic model of CD41 cells and, in parallel
Figure 3. Immunoblotting of anti-Fas specificities in sera from HIV-11
patients and uninfected controls. Although in the presence of undefined
bands related to weak reactivity with other antigens, the majority of IgG
binding the WC8 cells in the flow cytometry assay were reactive to a
43.8-kD antigen, that was also detected by the anti-Fas mAb from clone
CH11. Conversely, no evidence of reactivity was observed when using
the Fas-negative membrane (WR19L) as control (upper section). Sera from
patients unreactive to the CEM membrane and uninfected donors
showed no evidence of binding to the transfected antigen (lower section).
Numbers are related to patients and controls. IgG indicate the negative
control provided by 0.5 mg/ml of polyspecific IgG incubated with the
WC8-blotted membrane.2294 Anti-Fas Antibodies in HIV-11 Patients
tests, autologous T cells from the peripheral blood of the
four patients providing anti-Fas. Positive controls were
provided by the anti-Fas from clone CH11 and the rFas-L,
whereas purified IgG from two patients of group B (9 and
34) were used as negative controls to anti-Fas. Fig. 7 shows
the cytofluorimetric profiles of PI staining of treated CEM
cells. As depicted in section B, anti-Fas molecules induced
a remarkable increase of the subdiploid DNA peak that was
particularly evident at 20 mg/ml or higher concentrations,
when its extent ranged from z63.6 to 92.5%. Both control
IgG from patients unreactive to the CEM lysate failed to
induce any increase in the apoptotic cell population, whereas
as expected, the CH11 and the rFas-L control reagents drove
.90% of cells to die (Fig. 7 A). An extension of these ex-
periments included the evaluation of the subdiploid DNA
extent in HIV-1 T cells that had been incubated with au-
tologous anti-Fas. A similar pattern to CEM cells with oc-
casional further increment of the apoptotic population was
usually observed, whereas no evident differences were noted
with heterologous as opposed to autologous anti-Fas prep-
arations (data not shown). Fig. 7 C shows the effect of
anti-Fas inhibition by the VEINCTR peptide. Preincuba-
tion of anti-Fas antibodies with increasing concentrations
(0.5 to 7.5 mg/ml) of this peptide induced a major suppres-
sion of the apoptogen effect, leading to substantial recovery
of the euploid DNA peak (M2). This effect paralleled the
failure to react with rgp120 in control ELISA, and sup-
ported the specificity of the peptide for such anti-Fas ago-
nist molecules.
The inhibitive effect of anti-Fas antibodies on the prolif-
eration of CEM cells is also illustrated in Fig. 8 (left panel).
Anti-Fas from serum 54 showed the highest inhibition
([3H]thymidine uptake <35%) at a concentration .0.1
mg/ml. The similar profile obtained with the anti-Fas from
patient 41 at 1 mg/ml was significantly different (P ,0.02)
from the control cell preparations that were treated with
purified IgG from group B patients (uptake 100% with
z19,000 cpm). Slightly less inhibition was noted with the
anti-Fas from patients 3 and 59. Both preparations sup-
pressed [3H]thymidine uptake of CEM cells by z50%,
showing that antibody concentrations .1 mg/ml were still
effective in significantly suppressing their target cells (P
,0.05). A strong inhibition was induced by both CH11
and rFas-L reagents in control cell suspensions, though
their effect at 1 mg/ml was nearly equivalent to anti-Fas
preparations from patients 41 and 54. This confirms the
Figure 4. Reactivity to Fas by ELISA using the chimeric rFas-Fc protein in 16 HIV-11 sera showing positive binding to CEM membrane as compared
to 39 anti-CEM–negative sera. Specificity to Fas was predominantly expressed in all instances with respect to either total or IgM-mediated rheumatoid
activity. The highest values occurred in patients from groups A (3, 41, and 54) and C (28 and 59), showing serum elevations of T cell–reactive IgG,
whereas the sera from patients unreactive to CEM membrane showed mean values of weak affinity to the antigen. By contrast, control sera from four
HIV-1–uninfected patients with high RF titers reacted with Fc both in its chimeric and natural forms.2295 Silvestris et al.
susceptibility of CEM cells to activate their own Fas path-
way after cross-linking with these molecules.
A control of specificity in proliferative assays was also
provided using the same anti-Fas antibodies preincubated
with increasing amounts of rgp120. Fig. 8 (right panel)
shows that saturation of anti-Fas from the same patients
with .1 mg/ml of virus glycoprotein was able to prevent
the observed inhibition of proliferative rate in CEM cells
that were treated with 10 mg/ml of anti-Fas. In all in-
stances, the preincubation of these antibodies with a similar
concentration of rgp120 restored the normal proliferation
of those cells, suggesting the functional inactivation of anti-
Fas. Conversely, control IgG unreactive to CEM were not
influenced by the virus glycoprotein.
These cross-inhibiting experiments exploring the effect
of anti-Fas saturation with either VEINCTR in PI mea-
surement or rgp120 in proliferation supported the conten-
tion that our antibody preparations were specific for both
Fas and gp120 to an equivalent extent.
Affinity-isolated Fas-reactive IgG Bind to gp120. The abil-
ity of anti-Fas from the four patients to bind to HIV-1 gly-
coproteins was tested by immunoblotting. Fig. 9 shows the
reactivity to gp120 detected in WC8-absorbed anti-Fas
IgG from patient 54 compared with the serum pattern of
positivity to the virus lysate. Similar binding was observed
in IgG from patient 54 and 59, which were purified
through VEINCTR columns. A variable positivity of im-
munoblotting binding was also detected in the other three
preparations of anti-Fas derived from WC8-coupled col-
umns (data not shown).
Figure 5. (A) Epitope mapping of a domain
of Fas (aa position 90–117), including an 8-mer
stretch (VEINCTR—N) shared by the V3 loop
of gp120. A panel of 17 overlapping 10-mer
peptides used as antigens in ELISA revealed a
predominant affinity to that domain in sera 3,
41, and 54 although IgG from patient 54
showed a slight increase of reactivity to a sub-
sequent peptide constructed with (N) Asn in
the 108 aa position. Specificity to the
VEINCTR peptide was almost undetectable in
sera from patients unreactive to the CEM mem-
brane. (B) ELISA reactivity to synthetic pep-
tides resembling the homology sequence of the
aa 99–108 domain of Fas in the V3 loop of
HIV-1iiib (VEINCTRPNN) and HIV-1mn
(VQINCTRPNY) strains. OD values to both
peptides were apparently equivalent in most of
the anti-Fas IgG in groups A and C. In contrast,
sera 3, 21, and 41 showed a slight difference in
their affinity to the peptides, suggesting that the
replacement of E (Glu) by Q (Gln) was influ-
encing the antigenicity of the epitope.2296 Anti-Fas Antibodies in HIV-11 Patients
Discussion
The present study demonstrates that the described in-
crease of T cell apoptosis in HIV-1 infection could include
an antibody-mediated mechanism acting via the Fas path-
way. Analysis of serum reactivities in a cohort of HIV-11
patients revealed that IgG to CEM lymphoblast membrane
bound Fas in both quantitative cytofluorimetry and immu-
noblotting, using the human Fas-transfected mouse WC8
lymphoma as a substrate, and reacted with the rFas in ELISA.
Investigation of Fas epitope specificity by linear sequence
peptides documented prevalence of reactivity to a domain
including the 99VEINCTR–N108 peptide, also shared by
the gp120 V3 loop of HIV-1iiib. Absorption of sera by af-
finity columns coupling the WC8 membrane lysate pro-
vided enriched anti-Fas IgG preparations whose effect in
functional studies was nearly equivalent to either CH11
IgM anti-Fas mAb or rFas-L in induction of apoptosis in
target cells. These molecules were also reactive to a pecu-
liar epitope of gp120, however, suggesting that the hu-
moral response elicited to that domain of the HIV-1 enve-
lope protein may enhance T cell apoptosis by a molecular
mimicry mechanism involving Fas stimulation.
A number of studies have emphasized the role of auto-
immune mechanisms in the immunopathogenesis of AIDS.
Disturbance of self–nonself recognition resulting from
chronic activation of the immune system has been postu-
lated to promote differential autoimmune deregulations,
including GVHD condition (44), leukocyte alloimmuniza-
tion (45), abnormal idiotype interactions (46), and in-
creased cytokine secretion (47). Structural similarities be-
tween immunogenic HIV-1 envelope proteins and MHC
and other key immunoregulatory molecules have recently
been postulated (25, 26, 48) as the source of the chronic
immune derangements, leading to the production of auto-
antibodies and clinical phenomena. Despite the description
of peculiar syndromes that resemble idiopathic autoimmune
diseases (49), however, the occurrence of autoantibodies
that display pathogenic idiotypes which parallel and pro-
ceed to the late stages of disease have rarely been detected
in HIV-11 patients.
Although described in ,20% of HIV-1–infected indi-
Figure 6. SDS-PAGE pattern of isolated anti-Fas antibody preparations
obtained by absorption of sera on affinity columns coupled with the Fas1
membrane lysate from WC8 cells and further absorption on WR19L ly-
sate columns for clearance of nonspecific reactivities. A prevalent IgG
content was observed in those preparations, even though traces of IgM
were also present. Parallel absorptions using VEINCTR peptide–coupled
affinity columns provided eluates showing a similar content of antibodies
in sera 54 and 59. Standard IgM and IgG were myeloma proteins.
Figure 7. Functional studies
of isolated anti-Fas molecules
from patients 3, 41, 54, and 59.
(A) Percentage of apoptotic
CEM cells measured as the ex-
tent of PI subdiploid DNA stain-
ing (M1) induced by 20 mg/ml
of agonist ligands of Fas (CH11
mAb and rFas-L) compared to
the effect of control IgG from
two patients unreactive to CEM
membrane. (B) The extent of
subdiploid DNA in cell prepara-
tions that were treated with simi-
lar concentrations of the purified
anti-Fas from the four patients
ranged from z63–92%, and was
apparently equivalent to the ef-
fect of functional ligands. (C)
Preincubation of anti-Fas prepa-
rations with 7.5 mg/ml of
VEINCTR peptide removed the
ability of those antibodies to in-
crease the PI subdiploid DNA
peak, suggesting their functional
saturation by the related antigen.2297 Silvestris et al.
viduals (31, 50, 51), autoantibodies to T cell antigens are
suspected to contribute to the immunopathogenesis of AIDS,
since their serum levels may parallel the progression of lym-
phopenia (32, 33, 51). Molecular specificities to the HIV-1
receptor (52, 53) and other membrane antigens (30, 50, 54)
have been attributed to such antibodies in affecting the
helper function of CD41 cells, whereas using the CD41
clonotypic CEM lymphoblasts, we documented that a re-
ceptor of z43.5 kD was able to suppress the cytotoxic
properties of those antibodies in competitive inhibition ex-
periments (35). Evidence from this work strongly suggests
that the Fas antigen is the primary molecular target of such
T cell–reactive antibodies in a number of HIV-1–infected
individuals.
Fas is a 45-kD trimeric antigen that is involved in main-
taining both consistency of T cell level and self-tolerance
within the immune system. Accumulating evidence from
recent studies emphasizes the critical role of Fas interaction
with its trimeric ligand in the induction of antigen-primed
T cell apoptosis (13, 55, 56) and cytotoxic cell killing (17,
57). Further work from independent groups (28, 58) and
ourselves (29) reported that, as a result of chronic immune
activation related to HIV-1 infection, Fas is significantly
overexpressed by peripheral T cells, particularly during ad-
vanced disease, and that its responsiveness to differential
ligands regularly drives these cells to apoptosis even by
Figure 8. Inhibition of CEM proliferative rate by anti-Fas preparations. Significant inhibition (P ,0.02) was noted in cell suspensions that were incu-
bated with anti-Fas IgG from patients 41 and 54 by the concentration of 1 mg/ml. A moderate but significant effect (P ,0.05) was also recorded using
anti-Fas preparations 3 and 59 at higher concentrations. The test included both positive and negative controls. The effect of both CH11 mAb and rFas-L
was nearly equivalent to anti-Fas antibodies from patients, whereas the control Fas-unreactive IgG from patients 9 and 34 failed to induce significant vari-
ations of the baseline [3H]thymidine uptake (left panel). Preincubation of anti-Fas with rgp120 induced in all instances a dose-dependent suppression of
their inhibitory property on CEM proliferation, which was measured as the percentage of [3H]thymidine incorporation. The effect of control IgG was
not influenced by the recombinant glycoprotein (right panel).
Figure 9. Immunoblotting of isolated anti-Fas IgG from patient 54 on
the HIV-1 lysate, as compared with serum pattern of positivities to the vi-
ral bands. The antibody was found to react with gp120 in a fashion similar
to both antibody preparations (from patients 54 and 59) absorbed on
VEINCTR columns. Negative control using commercial human IgG was
also provided.2298 Anti-Fas Antibodies in HIV-11 Patients
cross-linking with the monomeric IgG1 anti-Fas mAb from
clone UB-2. This reagent is a weak inducer of apoptosis in
Fas1 cell lines, whereas it may costimulate the proliferation
of freshly isolated T cells from uninfected donors (16).
Therefore, both overexpression and susceptibility of Fas
during HIV-1 infection may be crucial in the increase of
peripheral T cell apoptosis.
The main question raised by this study is whether the
Fas-reactive IgG detected in several patients are actually
implicated in enhancing the extent of T cell apoptosis in
vivo. The first answer came from indirect multiparametric
analysis. Semiquantitative measurement of the cytofluori-
metric PI intensity of DNA staining was enough to show
that patients from groups A and C with the highest ELISA
reactivities to rFas (Fig 4) showed a parallel increment of
their subdiploid DNA T cell population (Table 1). Al-
though the differences between percentages of apoptotic T
cells were estimated in a comparatively small number of pa-
tients within each group, these data suggest a potential as-
sociation between the occurrence of anti-Fas antibodies
and an increase of apoptosis-mediated lymphopenia. This
was manifest particularly in patients with advanced disease
from both groups A and C. Meyaard et al. (7) have re-
ported that the degree of T cell apoptosis may not correlate
with disease progression. Accordingly, the potential linkage
of uniformly accelerated cell death in patients with differ-
ent CDC stages may depend on their serum elevations of
IgG reactive to Fas. Despite the described association,
however, our group observed extensive subdiploid DNA
content in peripheral T cells from a few patients lacking se-
rum positivities to either Fas1 cell membranes or rFas, thus
supporting the assumption that, besides Fas, other mecha-
nisms are involved in driving the increased T cell apoptosis
in such patients.
A second interesting point concerned the effect of Fas-
reactive IgG in functional studies. These molecules were
absorbed by affinity chromatography on Fas1 membrane
from WC8 cells and were demonstrated to promptly en-
hance the subdiploid DNA peak in cultured CEM cells, re-
sulting in an event similar to that provoked by reagents that
trigger Fas, such as the CH11 mAb and rFasL (Fig. 7, A
and B). Conversely, no effect was observed in control tests
using purified IgG that was unreactive to CEM membrane
from two patients (Nos. 9 and 34) of group B. These find-
ings were also sustained by the proliferative assays shown in
Fig. 8. Again, the presence of anti-Fas preparations at 1 mg/ml
or more, particularly from patients 41 and 54, induced a
tremendous inhibition of the [3H]thymidine uptake in a
fashion similar to that obtained with functional reagents.
The agonist effect of these purified anti-Fas was also cross-
inhibited by either VEINCTR or rgp120, resulting in a
dose-dependent lack of activity in both functional tests.
Since control IgG preparations were ineffective, we con-
cluded that such affinity-isolated anti-Fas were able to acti-
vate cytolysis of CEM cells by mimicking the natural Fas-L.
Although we obtained equivalent results in experiments us-
ing autologous T cells, we reasoned that CEM lympho-
blasts were an appropriate CD41 cell target to avoid the
heterogeneity of peripheral lymphocytes at different steps
of maturation.
Fine mapping of Fas using a panel of 10-mer overlapping
peptides revealed that the entire epitope (VEINCTR–N)
shared by the V3iiib loop of gp120 was highly reactive to
the majority of sera from groups A and C (Fig. 5). With the
exception of three sera (Nos. 3, 21, and 41), we found that
the binding to IIIB (VEINCTRPNN) and MN (VQINC-
TRPNY) HIV-1 peptides was almost equivalent, and that
replacement of Glu by Gln did not influence the relative
antibody affinity. By contrast, the presence of Asn on both
peptides slightly increased the reactivity of IgG from serum
54, suggesting that a conformational domain of gp120, in-
cluding Asn, was predominantly recognized by this patient.
Conformational V3 loop peptides have been reported to
induce specific antibody response to HIV-1 (59). Since the
majority of neutralizing antibodies to both IIIB and MN
European strains of HIV-1 are prevalently directed to the
gp120 V3 loop (42), however, our data suggest that within
the wide humoral response to virus, only IgG elicited to
that domain of the V3 loop are effective cross-linkers of Fas
and are able to induce its trimerization. In this context, it
has been demonstrated by Itoh et al. that the cytoplasmic
signal–transducing domain of Fas, also termed death do-
main, is activated by receptor clustering (60). Therefore,
the oligomerization of Fas by such anti-V3 IgG may ac-
count for the property of these molecules to cross-link the
receptor in a self-associated molecular state.
In conclusion, our data indicate that the T cell–reactive
antibodies originally described in HIV-1 infection are actu-
ally involved in aggravating the lymphopenia, although
their mechanism is not complement-mediated cytolysis.
Fas-mediated depletion of peripheral T cells may occur as
an effect of the humoral response to HIV-1, and is appar-
ently dependent on the fine specificity of IgG to gp120.
Since these antibodies react with the described sequence of
Fas, it would be of interest to determine the potential reac-
tivity to VEINCTR–N as a screening procedure to select
the patients at higher risk of severe lymphopenia, based on
autologous Fas activation.
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